Donald Bellgrau

Fondateur chez ApopLogic Pharmaceuticals, Inc.

Consumer Services

Health Technology

Postes actifs de Donald Bellgrau

Sociétés	Poste	Début	Fin
The University of Colorado	Corporate Officer/Principal	14/09/2009	-
ApopLogic Pharmaceuticals, Inc. ApopLogic Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ApopLogic Pharmaceuticals, Inc. researches and develops pharmaceutical products. It focuses on the development and commercialization of B201, is a rationally-designed synthetic peptide dimer of a potent decapeptide bradykinin B1&B2 receptor antagonist that directly induces apoptosis of cancer cells that overexpress these receptors and AP-300 is used in the neo-adjuvant or adjuvant setting with standard-of-care agents to improve survival outcomes in humans and companion animals with any accessible solid tumor including carcinomas, sarcomas and lymphomas. The company was founded in 2006 by Richard C. Duke, Donald Bellgrau, Paul A. Bunn, Daniel Chan, Lajos Gera, Jaime F. Modiano and John M. Stewart and is headquartered in Aurora, CO.	Directeur/Membre du Conseil	01/01/2006	-
	Fondateur	01/01/2006	-

Sociétés	Poste	Début	Fin
GLOBEIMMUNE, INC.	Fondateur	10/02/1995	-
Basel Institute for Immunology	Corporate Officer/Principal	-	-

University of Pennsylvania

Doctorate Degree

Internationale

Etats-Unis	5
Suisse	2

Opérationnelle

Corporate Officer/Principal	2
Founder	2
Doctorate Degree	1

Sectorielle

Consumer Services	4
Health Technology	3

Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Sociétés cotées	1
GLOBEIMMUNE, INC.	Health Technology

Entreprise privées	1
ApopLogic Pharmaceuticals, Inc. ApopLogic Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ApopLogic Pharmaceuticals, Inc. researches and develops pharmaceutical products. It focuses on the development and commercialization of B201, is a rationally-designed synthetic peptide dimer of a potent decapeptide bradykinin B1&B2 receptor antagonist that directly induces apoptosis of cancer cells that overexpress these receptors and AP-300 is used in the neo-adjuvant or adjuvant setting with standard-of-care agents to improve survival outcomes in humans and companion animals with any accessible solid tumor including carcinomas, sarcomas and lymphomas. The company was founded in 2006 by Richard C. Duke, Donald Bellgrau, Paul A. Bunn, Daniel Chan, Lajos Gera, Jaime F. Modiano and John M. Stewart and is headquartered in Aurora, CO.	Health Technology

Entreprise privées

Health Technology